Cargando…

Relationship between the Expression of BRAF V600E and Ki-67 with the Recurrence of Well-Differentiated Thyroid Cancer

OBJECTIVE: This study aims to determine the relationship between BRAF V600E and Ki-67 expression with the recurrence of well-differentiated thyroid cancers. METHOD: The design of this study is a case-control and survival analysis. The data was taken from the thyroid cancer registry in Padang, Indone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harahap, Wirsma Arif, Tofrizal, Tofrizal, Oktahermoniza, Oktahermoniza
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	West Asia Organization for Cancer Prevention 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930947/ https://www.ncbi.nlm.nih.gov/pubmed/36444572 http://dx.doi.org/10.31557/APJCP.2022.23.11.3617

Ejemplares similares

The RYR3 gene is involved in Wharton’s jelly derived mesenchymal stem cell treatment of Alzheimer’s disease in rats
por: Ali, Hirowati, et al.
Publicado: (2023)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
por: Yan, Changjiao, et al.
Publicado: (2019)

Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma
por: Bui Dang Minh, Tri, et al.
Publicado: (2023)

Association of microRNA Expression and BRAF(V600E) Mutation with Recurrence of Thyroid Cancer
por: Pamedytyte, Daina, et al.
Publicado: (2020)

BRAF(V600E) mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas
por: Takano, T, et al.
Publicado: (2007)

Vitamin E ameliorates testicular histological features and androgen binding protein levels in testicle of rats induced by allethrin
por: Sukmawati, Yofa, et al.
Publicado: (2019)

The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors
por: Choi, Sun Yi, et al.
Publicado: (2013)

Prognostic Factors of Local-Regional Recurrence in Patients with Operable Breast Cancer in Asia: A Meta-Analysis
por: Harahap, Wirsma Arif, et al.
Publicado: (2019)

BRAF(V600E) Positivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
por: Park, Joonseon, et al.
Publicado: (2023)

Comparative BRAF V600E immunohistochemical expression in differentiated thyroid tumors with papillary features
por: Wahid, Maha Hatem Abdul, et al.
Publicado: (2022)

Ki-67 and CK-19 are predictors of locoregional recurrence in papillary thyroid carcinoma
por: Viana, Aline de Oliveira Ribeiro, et al.
Publicado: (2020)

Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer
por: Murugan, Avaniyapuram Kannan, et al.
Publicado: (2016)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

The BRAF(V600E) mutation: what is it really orchestrating in thyroid cancer?
por: Nucera, Carmelo, et al.
Publicado: (2010)

Clinical implication of the BRAF(V600E) mutation in papillary thyroid carcinoma
por: Kim, Yong-Seok, et al.
Publicado: (2013)

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma
por: HE, GUOPING, et al.
Publicado: (2014)

BRAF V600E and lymph node metastases in papillary thyroid cancer
por: Chen, Pan, et al.
Publicado: (2020)

Preoperative BRAF(V600E) mutation detection in thyroid carcinoma by immunocytochemistry
por: Swan, Kristine Zøylner, et al.
Publicado: (2022)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Utility of BRAF V600E mutation detection in cytologically indeterminate thyroid nodules
por: Rowe, Leslie R, et al.
Publicado: (2006)

Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer
por: Huillard, Olivier, et al.
Publicado: (2017)

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer
por: Robbins, Richard J., et al.
Publicado: (2020)

Artificial intelligence to predict the BRAF(V600E) mutation in patients with thyroid cancer
por: Yoon, Jiyoung, et al.
Publicado: (2020)

Risk and Prognostic Factors for BRAF(V600E) Mutations in Papillary Thyroid Carcinoma
por: Wei, Xiaojing, et al.
Publicado: (2022)

Induction of the BRAF(V600E) Mutation in Thyroid Cells Leads to Frequent Hypermethylation
por: Yi, Jin Wook, et al.
Publicado: (2022)

BRAF V600E and Novel Somatic Mutations in Thyroid Cancer of Libyan Patients
por: Tounsi-Guettiti, Haifa, et al.
Publicado: (2022)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
por: Lang, Matthias, et al.
Publicado: (2023)

Sacral metastases in a patient with BRAF V600E+ papillary thyroid carcinoma
por: Bhethanabotla, Rohith M, et al.
Publicado: (2023)

The BRAF(V600E) mutation analysis and risk stratification in papillary thyroid carcinoma
por: Scheffel, Rafael Selbach, et al.
Publicado: (2020)

Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma
por: Li, Qian, et al.
Publicado: (2017)

Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma
por: Huang, Lihua, et al.
Publicado: (2018)

Histochemical Analysis of Laminin α Chains in Diethylstilbestrol-Induced Prolactinoma in Rats
por: Ramadhani, Dini, et al.
Publicado: (2015)

Value of TIRADS, BSRTC and FNA-BRAF(V600E) mutation analysis in differentiating high-risk thyroid nodules
por: Zhang, Yu-zhi, et al.
Publicado: (2015)

Differentiating Benign from Malignant Thyroid Tumors by Kinase Activity Profiling and Dabrafenib BRAF V600E Targeting
por: Hilhorst, Riet, et al.
Publicado: (2023)

The relationship between the expression of Ki-67 and the prognosis of osteosarcoma
por: Zeng, Ming, et al.
Publicado: (2021)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67
por: Genç, C. G., et al.
Publicado: (2018)

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)

Diagnostic utility of BRAF(V600E )mutation testing in thyroid nodules in elderly patients
por: Guerra, Anna, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_888sk1hlf13r6flqsr62us7kn9